EXPERIENCE OF USING SELECTIVE LPS-SORBTION IN THE COMBINED THERAPY OF THOSE SUFFERING FROM GRAM-NEGATIVE SEPSIS

Sepsis remains to be a global medical problem associated with high mortality level. Due to this, there is constant interest towards investigation of its pathogenesis and introduction of new management techniques. Current recommendations contain clear instructions for intensive care including substitutive renal therapy in case of renal dysfunction, however other methods of extracorporal detoxification including selective sorbtion of endotoxin are still being discussed. Goal: to demonstrate the opportunities of selective LPS-sorbtion in the combined therapy of those suffering from septic shock using a specific clinical case. Results: Immediately after selective hemosorption the patient with septic shock demonstrated the following positive changes: reduction of body temperature down to low-grade fever, stabilization of hemodynamic rates, reduction of noradrenaline dose from 0.2 to 0.05 mkg (kg ∙ min-1), reduction of lactate level from 2.3 to 1.7 mmol/L and improvement of respiratory function rates. The renal function improved against the background of stabilization of hemodymanic rates, thus serum creatinine reduced from 0.309 to 0.150 mmol/L. The substitutive renal therapy was fully stopped on the 9th day. The intensity of clinical manifestations of multi-organ dysfunction reduced from 10 to 4 according to SOFA score. Conclusion. Clinical follow-up demonstrated the positive experience of using selective LPS-sorbtion in the combined therapy of septic shock, caused by gram-negative bacteria. Express test for endotoxin activity level in the septic shock patients enhances the objectivity of choice of extracorporal hemocorrection methods.

1. Benedict R.G., Langlykke A.F. Antibiotic activity of Bacillus polymyxa. J. Bacteriology, 1947, vol. 54, pp. 24.

2. Beutler B., Milsark I.W., Cerami A.C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science, 1985, vol. 229, no. 4716, pp. 869-871.

3. Brade H. Endotoxin in Health and Disease. CRC Press, 1999, pp. 7-9.

4. Dinna N. Cruz, Antonelli M., Fumagalli R., Foltran F., Donati A. Early Use of Polymyxin B Hemoperfusion in Abdominal Septic Shock. The EUPHAS Randomized Controlled Trial. JAMA, 2009, vol. 301, no. 23, pp. 2445-2452.

5. Heumann D., Roger T. Initial responses to endotoxins and Gram-negative bacteria. Clin. Chimica Acta., 2002, vol. 323, no. 1-2, pp. 59-72.

6. Klein D., Monti G., Bottiroli S et al. Clinical assessment does not predict endotoxemia in septic shock. Crit. Care Med., 2009, vol. 37, no. 12, pp. 462.

7. Klein D., Foster D., Schorr C., Kazempour K., Walker P., Dellinger P. The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial. BioMed. Central, 2014, no. 6, pp. 23-28.

8. Kodama M., Aoki H., Tani T. Selective sorbent hemoperfusion for endotoxin. Artificial Liver Support, 1992, no. 11, pp. 181-196.

9. Nakamura T., Ebihara L., Shoji H. et al. Treatment with polymyxin B immobilized fiber reduces platelet activation in septic shock patients: decrease in plasma levels of soluble P-selectin, platelet factor-4 and betathromboglobulin. Inflammation Research, 1999, vol. 48, no. 4, pp. 171–175.

10. Ono S., Tsujinomoto H., Matsumoto A. et al. Modulation of human leukocyte antigen-DR on monocytes and CD16 on granulocytes in patients with polymyxin В immobilized fiber. Am. J. Surgery, 2004, vol. 188, no. 32, pp. 150-156.

11. Pfeiffer R. Untersuchungen uber das Choleragift. Z. Hygiene, 1892, no. 11, pp. 393-412.

12. Ronco C., Fernandes M., Watanabe M., Dezoti da Fonseca C. Polymyxin B Nephrotoxicity: From Organ to Cell Damage; Public Library of Science One. 2016, no. 17, pp. 48-51.

13. Ronco C., Cutuli S.L., Artigas A., Fumagalli R., Monti G., Ranieri V.M., Antonelli M. (Collaborative Group) Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry. EUPHAS 2. Collaborative Group Ann. Int. Care, 2016, no. 6 (1), pp. 77.

14. Stansly P.G., Schlosser M.E. Studies on polymyxin: isolation and identification of Bacillus polymyxa and differentiation of polymyxin from certain known antibiotics. J. Bacteriology, 1947, vol. 54, no. 5, pp. 549-556.

15. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock. Int. Care Med., 2017, vol. 43, pp. 304-377.

16. Tani T., Hanasawa K., Kodama M. et al. Correlation between plasma endotoxin, plasma cytokines, and plasminogen activator inhibitor-1 in septic patients. World J. Surgery, 2001, vol. 25, no. 5, pp. 660-668.

17. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 2016, vol. 315, no. 8, pp. 801-810.